Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab
- 1 December 2018
- Vol. 73 (12), 2406-2408
- https://doi.org/10.1111/all.13586
Abstract
No abstract availableFunding Information
- Novartis
- Genentech
This publication has 11 references indexed in Scilit:
- Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticariaThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab TherapyActa Dermato Venereologica, 2017
- Autoimmune chronic spontaneous urticaria: What we know and what we do not knowJournal of Allergy and Clinical Immunology, 2017
- Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticariaJournal of Allergy and Clinical Immunology, 2017
- Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skinTheranostics, 2017
- Definition, aims, and implementation of GA2LEN Urticaria Centers of Reference and ExcellenceAllergy, 2016
- Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trialsJournal of Allergy and Clinical Immunology, 2016
- Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticariaThe Journal of Allergy and Clinical Immunology: In Practice, 2015
- Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysisJournal of Dermatological Science, 2014
- IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria?PLOS ONE, 2011